drugset / Trial / NCT07293325
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
Timeline
- Start
- 2025-06-02
- Primary completion
- 2027-04-02
- Completion
- 2027-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 1500 mg | Oral |
| Comparator | Metformin | Small molecule | 2000 mg | Oral |
| Subject | Semaglutide | Peptide | 2 mg | Subcutaneous |
| Subject | Tirzepatide | Peptide | 10 mg | Subcutaneous |